EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Immunomodulatory Effects of Microbiota-Derived Short-Chain Fatty Acids in Autoimmune Liver Diseases

Weici Zhang, Charles R Mackay iD, M Eric Gershwin iD

The Journal of Immunology · 01.06.2023 · 210 (11) · 1629-1639

DOI: 10.4049/jimmunol.2300016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Immunology, online erschienen am 01.06.2023. Verfasst von Weici Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Allergy, and Clinical Immunology, School of Medicine, University of California Davis, CA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Microbiota, Hepatitis, Autoimmune. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, HHS | NIH | NIDDK, American Association for the Study of Liver Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonpathogenic commensal microbiota and their metabolites and components are essential to maintain a tolerogenic environment and promote beneficial health effects. The metabolic environment critically impacts the outcome of immune responses and likely impacts autoimmune and allergic responses. Short-chain fatty acids (SCFAs) are the main metabolites produced by microbial fermentation in the gut. Given the high concentration of SCFAs in the gut and portal vein and their broad immune regulatory functions, SCFAs significantly influence immune tolerance and gut–liver immunity. Alterations of SCFA-producing bacteria and SCFAs have been identified in a multitude of inflammatory diseases. These data have particular significance in primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis because of the close proximity of the liver to the gut. In this focused review, we provide an update on the immunologic consequences of SCFA-producing microbiota and in particular on three dominant SCFAs in autoimmune liver diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeMicrobiotaHepatitis, AutoimmuneHumansFatty Acids, VolatileImmunity

Substanzen

Fatty Acids, Volatile

Autor:innen und Institutionen

  • Division of Rheumatology, Allergy, and Clinical Immunology, School of Medicine, University of California Davis, CA.
  • Department of Microbiology, Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Melbourne, Australia.

ORCID-Profile: Charles R Mackay, M Eric Gershwin

Förderung

  • NIDDK NIH HHS
  • HHS | NIH | NIDDK
  • American Association for the Study of Liver Diseases

Zitieren

APA

Zhang, W., Mackay, C. R., & Gershwin, M. E. (2023). Immunomodulatory Effects of Microbiota-Derived Short-Chain Fatty Acids in Autoimmune Liver Diseases. The Journal of Immunology, 210(11), 1629-1639. https://doi.org/10.4049/jimmunol.2300016

Vancouver

Zhang W, Mackay CR, Gershwin ME. Immunomodulatory Effects of Microbiota-Derived Short-Chain Fatty Acids in Autoimmune Liver Diseases. The Journal of Immunology. 2023;210(11):1629-1639. doi:10.4049/jimmunol.2300016

BibTeX
@article{Zhang2023,
  author = {Zhang, Weici and Mackay, Charles R and Gershwin, M Eric},
  title = {Immunomodulatory Effects of Microbiota-Derived Short-Chain Fatty Acids in Autoimmune Liver Diseases},
  journal = {The Journal of Immunology},
  year = {2023},
  volume = {210},
  number = {11},
  pages = {1629--1639},
  doi = {10.4049/jimmunol.2300016}
}
Kostenlos starten →